MetaStat, Inc. completed a trial of its MetaSite Breast test that confirmed the test's ability to accurately predict whether breast cancer would metastasize. The confirmation paves the way for MetaStat to bring the test to market in 2015. The company predicts that the test could be used to design more customized treatment for 100% of the 232,000 newly diagnosed breast cancer patients every year.

That represents a $580 million market opportunity for MetaSite Breast test. The most recent trial followed 481 women who had been diagnosed with breast cancer. Researchers from Albert Einstein College of Medicine and of Yeshiva College and Weill Cornell Medical College used the MetaSite Breast test on each of the 481 women.

They found that there was a significant correlation between the tests' predictions and the women whose cancer did metastasize. MetaSite Breast test is just one of MetaStat's products aimed at identifying cancerous tumors with the potential to metastasize. MenaCalc is a diagnostic test that predicts metastasis based on the amount of Mena protein isoforms that exist in a cancerous tumor sample.

That test is scheduled for release between 2015 and 2018 and could be used to predict metastasization in patients with breast, lung, prostate, and colorectal cancer.